CHEST Highlights

INCREASE OLE was the open-label extension of the INCREASE study (NCT02630316), which investigated the safety and efficacy of inhaled treprostinil in patients with pulmonary hypertension due to interstitial lung disease. We caught up with Prof. Jean Elwing (UC Health, Cincinnati, OH, USA) to discuss the methodology, inclusion criteria, and safety and tolerability findings from the […]

Alpha-1 antitrypsin deficiency (AATD) is a genetic disorder that remains highly undiagnosed. It is estimated that between 1 to 5% of patients with chronic obstructive pulmonary disease (COPD) have AATD; however is often not diagnosed. We caught up with Prof. Charlie Strange (MUSC, Charleston, SC, USA) to discuss what methods are currently available for the […]

CHEST 2022 took place between October 16-19 in Nashville, TN, we interviewed editorial board member Prof. Margaret Pisani (Yale School of Medicine. New Haven, CT, USA) around her personal congress highlights and the networking opportunities which were available on site. Questions What CHEST presentations had the greatest impact this year and what were your personal […]

Once-nightly sodium oxybate (FT218) is currently being investigated in the open label phase 3 study RESTORE (NCT04451668) for the treatment of narcolepsy. We caught up with Prof. John Harsh (University of Colorado Boulder, Boulder, CO, USA) to discuss the aims, design, inclusion criteria and interim findings of the RESTORE study. The abstract ‘LONG-TERM SAFETY OF […]

INSPIRE (LTI-301 clinical trial) was a phase 3 study investigating the long-term safety and tolerability of LIQ861 in patients with pulmonary arterial hypertension (NCT03399604). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) around the aims, design and eligibility criteria of the LTI-301 clinical trial and the findings from […]

LIQ861 is an investigational, inhaled dry powder formulation of treprostinil delivered through a device, which currently has tentative approval from the FDA for the treatment of pulmonary arterial hypertension (PAH). touchRESPIRATORY were delighted to talk with Dr. Marc Simon (UCSF Health, San Francisco, CA, USA) about LIQ861 and its potential advantages over conventional formulations of […]

Cannabis use disorder is described as the inability to stop using marijuana, despite a negative impact on health. It was a pleasure to talk with Dr. Advait Vasavada (M. P. Shah Medical College, Jamnagar, India) around the aims, design, eligibility criteria and findings from his study investigating in-hospital mortality of pulmonary embolism in young adults […]

Cannabis use disorder is described as the inability to stop using marijuana, despite a negative impact on health. We caught up with Dr. Advait Vasavada (M. P. Shah Medical College, Jamnagar, India) around the definition of cannabis use disorder and what we currently know about the impact of this disorder on thromboembolic events. The abstract […]

Herpes Zoster (HZ) infection is a vaccine-preventable disease that occurs when a previous infection with varicella-zoster virus (VZV) is reactivated; patients with chronic obstructive pulmonary disease (COPD) and asthma have suppressed immunity and therefore are at a higher risk of being infected and experiencing complications. We caught up with Dr. Barbara Yawn (University of Minnesota, […]